PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

Inclusion Criteria: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Patient is at least 18 years of age at the time of study enrollment. 2. Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment). 3. Patient is initiating new Eligible Medication for the first time for the treatment of PSO. 4. Patient is willing and able to provide informed consent to participate in this study. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in the study: 1. Patient is participating in a blinded clinical trial. 2. Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study. 3. Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. B. Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.